The market for biopharmaceutical financings in 2018 was remarkable in many ways, including the record-breaking level of venture capital investment, the year's 68 drug developer initial public offerings in the US, and the emergence of Chinese companies as major cash magnets.
In examining the largest deals across financing categories – venture capital, IPOs and follow-on public offerings (FOPOs) – one company,...






